Home|Journals|Articles by Year|Audio Abstracts

Original Research

Investigation of prognostic significance of CD44 expression in women with vulvar squamous cell carcinoma

Yakup Yalcin, Serenat Eris Yalcin, Selda Uysal, Burak Tatar, And Yavuz, Mehmet Ozgur Akkurt, Seyran Yigit.


The aim of our study is to evaluate whether CD 44 isoform expression is a prognostic factor in vulvar carcinom and to correlate the expression with clinicopathological parameters. Methods: The study included 26 patients diagnosed with invasive squamous cell vulvar cancer. The data of patients were obtained from the oncology follow-up records and the hospital database. The haemotoxylene & eosin stained preparates of the cases were removed from the archives and re-evaluated by examination of the slides under a light microscope. The preparates of the patients were evaluated separately according to the extent and intensity of staining and the combined score applied with the immunohistochemical method in the anti-CD44 antibody in the epithelium and the stroma. Results: When the CD44 epithelial staining intensity and staining combined scores of the patients were examined according to other clinicopathological parameters, a statistically significant difference was found between the groups in terms of tumour grade, differentiation, age, lymph node positivity, and survival rates (p

Key words: CD44, expression, vulva, vulvar carcinom

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.